Logo image of CREX

CREATIVE REALITIES INC (CREX) Stock Fundamental Analysis

NASDAQ:CREX - US22530J3095 - Common Stock

2.34 USD
+0.01 (+0.43%)
Last: 9/5/2025, 4:30:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CREX. CREX was compared to 99 industry peers in the Media industry. CREX has a bad profitability rating. Also its financial health evaluation is rather negative. CREX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

CREX had positive earnings in the past year.
CREX had a negative operating cash flow in the past year.
In multiple years CREX reported negative net income over the last 5 years.
In multiple years CREX reported negative operating cash flow during the last 5 years.
CREX Yearly Net Income VS EBIT VS OCF VS FCFCREX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

CREX has a Return On Assets of -0.05%. This is comparable to the rest of the industry: CREX outperforms 55.56% of its industry peers.
The Return On Equity of CREX (-0.10%) is comparable to the rest of the industry.
The Return On Invested Capital of CREX (0.43%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -0.05%
ROE -0.1%
ROIC 0.43%
ROA(3y)-2.23%
ROA(5y)-17.47%
ROE(3y)-5.54%
ROE(5y)-80.4%
ROIC(3y)N/A
ROIC(5y)N/A
CREX Yearly ROA, ROE, ROICCREX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Operating Margin of CREX (0.60%) is worse than 61.62% of its industry peers.
CREX's Gross Margin of 46.99% is in line compared to the rest of the industry. CREX outperforms 54.55% of its industry peers.
CREX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.6%
PM (TTM) N/A
GM 47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.36%
GM growth 5Y1.66%
CREX Yearly Profit, Operating, Gross MarginsCREX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CREX is destroying value.
The number of shares outstanding for CREX has been increased compared to 1 year ago.
CREX has more shares outstanding than it did 5 years ago.
CREX has a worse debt/assets ratio than last year.
CREX Yearly Shares OutstandingCREX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CREX Yearly Total Debt VS Total AssetsCREX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.07, we must say that CREX is in the distress zone and has some risk of bankruptcy.
CREX has a worse Altman-Z score (0.07) than 68.69% of its industry peers.
A Debt/Equity ratio of 0.78 indicates that CREX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.78, CREX perfoms like the industry average, outperforming 52.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z 0.07
ROIC/WACC0.06
WACC7.14%
CREX Yearly LT Debt VS Equity VS FCFCREX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

CREX has a Current Ratio of 1.23. This is a normal value and indicates that CREX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CREX (1.23) is comparable to the rest of the industry.
CREX has a Quick Ratio of 1.10. This is a normal value and indicates that CREX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CREX (1.10) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.1
CREX Yearly Current Assets VS Current LiabilitesCREX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 488.89% over the past year.
The Revenue has grown by 12.59% in the past year. This is quite good.
CREX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.98% yearly.
EPS 1Y (TTM)488.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y40.23%
Revenue growth 5Y9.98%
Sales Q2Q%-0.65%

3.2 Future

Based on estimates for the next years, CREX will show a very strong growth in Earnings Per Share. The EPS will grow by 53.47% on average per year.
CREX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.65% yearly.
EPS Next Y144.82%
EPS Next 2Y53.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.24%
Revenue Next 2Y12.65%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CREX Yearly Revenue VS EstimatesCREX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CREX Yearly EPS VS EstimatesCREX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 6.69 indicates a rather cheap valuation of CREX.
Compared to the rest of the industry, the Price/Earnings ratio of CREX indicates a rather cheap valuation: CREX is cheaper than 89.90% of the companies listed in the same industry.
CREX is valuated cheaply when we compare the Price/Earnings ratio to 27.06, which is the current average of the S&P500 Index.
CREX is valuated rather expensively with a Price/Forward Earnings ratio of 19.95.
Based on the Price/Forward Earnings ratio, CREX is valued a bit cheaper than the industry average as 61.62% of the companies are valued more expensively.
CREX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.69.
Industry RankSector Rank
PE 6.69
Fwd PE 19.95
CREX Price Earnings VS Forward Price EarningsCREX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CREX is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.8
CREX Per share dataCREX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CREX's earnings are expected to grow with 53.47% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y53.47%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for CREX!.
Industry RankSector Rank
Dividend Yield N/A

CREATIVE REALITIES INC

NASDAQ:CREX (9/5/2025, 4:30:01 PM)

2.34

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners15.67%
Inst Owner Change24.48%
Ins Owners17.62%
Ins Owner Change25.71%
Market Cap24.62M
Analysts84
Price Target6.76 (188.89%)
Short Float %2.52%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)230.68%
Min EPS beat(2)-140.1%
Max EPS beat(2)601.45%
EPS beat(4)3
Avg EPS beat(4)160.43%
Min EPS beat(4)-140.1%
Max EPS beat(4)601.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-11.52%
Max Revenue beat(2)4.23%
Revenue beat(4)3
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-11.52%
Max Revenue beat(4)4.23%
Revenue beat(8)3
Avg Revenue beat(8)-4.2%
Revenue beat(12)3
Avg Revenue beat(12)-4.26%
Revenue beat(16)3
Avg Revenue beat(16)-3.68%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.76%
EPS NY rev (1m)-65.06%
EPS NY rev (3m)166.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.37%
Revenue NY rev (1m)-4.61%
Revenue NY rev (3m)-4.63%
Valuation
Industry RankSector Rank
PE 6.69
Fwd PE 19.95
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB N/A
EV/EBITDA 9.8
EPS(TTM)0.35
EY14.96%
EPS(NY)0.12
Fwd EY5.01%
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS4.59
BVpS2.84
TBVpS-1.8
PEG (NY)0.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.05%
ROE -0.1%
ROCE 0.55%
ROIC 0.43%
ROICexc 0.44%
ROICexgc 6.2%
OM 0.6%
PM (TTM) N/A
GM 47%
FCFM N/A
ROA(3y)-2.23%
ROA(5y)-17.47%
ROE(3y)-5.54%
ROE(5y)-80.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.36%
GM growth 5Y1.66%
F-Score3
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA 4.93
Cap/Depr 58.56%
Cap/Sales 5.37%
Interest Coverage 0.26
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.1
Altman-Z 0.07
F-Score3
WACC7.14%
ROIC/WACC0.06
Cap/Depr(3y)115.1%
Cap/Depr(5y)95.1%
Cap/Sales(3y)8.11%
Cap/Sales(5y)6.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)488.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-183.33%
EPS Next Y144.82%
EPS Next 2Y53.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y40.23%
Revenue growth 5Y9.98%
Sales Q2Q%-0.65%
Revenue Next Year4.24%
Revenue Next 2Y12.65%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-78.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year709.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-151.33%
OCF growth 3Y93.04%
OCF growth 5YN/A